30 closest matches · ranked by relevance
Pediatric Heart Failure
Primary: Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Maximum Drug Concentration in Plasma (Cmax) — 523; 179; 1970; 549 nanograms per…
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Primary: Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline — 22.8 percentage of participants
Heart Failure · Respiratory Failure
Primary: ICU-Free Days — 20; 19.4 Days
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Heart Failure
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 1 Participants
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days
HIV Infections
Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27
Dilated Cardiomyopathy
Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants
Heart Defects, Congenital · Heart Failure, Congestive
Primary: Weight-for-age Z-score at 14 Months of Age — -0.62; -0.42 standard deviation — p=0.28
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
Heart Failure · Heart Diseases · Cardiovascular Diseases
Primary: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) — 36.1; 31.4; 63.1; 52.1 units on a scale — p=0.1641
Heart Failure
Primary: Number of Participants With Adverse Events — 111; 78 Participants
Pediatric ALL
Primary: Bias of FloTrac Arterial Pressure Cardiac Output (L/Min) Against Swan Ganz Invasive Cardiac Output — 0.49 L/min
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
CHF
Primary: Number of Participants With Treatment Related AEs and Serious Adverse Events (SAEs) — 0 Participants
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2
Congenital Diaphragmatic Hernia · Persistent Pulmonary Hypertension of the Newborn · Hypoxemic Respiratory Failure
Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale
Congenital Heart Disease
Primary: Acetaminophen Serum Concentrations — 19; 17; 13; 13 mcg/mL
Heart Defects, Congenital · Hyperglycemia
Primary: Incidence of Nosocomial Infections in the Cardiac ICU — 8.6; 9.9 infections / 1000 pt days
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Heart Failure · Cardiomyopathies
Primary: The Safety of EXCOR® Pediatric Was Evaluated by Summarizing the Serious Adverse Event Rate Experienced While the Subject Was Supported on the Device. — 0.068; 0.066…
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days